Higher EUTOS Risk Scores Linked With Delayed Response Rate in CML

Share this content:
European patients with chronic myeloid leukemia who have high EUTOS risk scores achieved response much later than patients with low EUTOS risk scores.
European patients with chronic myeloid leukemia who have high EUTOS risk scores achieved response much later than patients with low EUTOS risk scores.

European patients with chronic myeloid leukemia (CML) who have high European Treatment and Outcome Study (EUTOS) risk scores achieved complete cytogenic response (CCyR) and major molecular response (MMR) much later than patients with low EUTOS risk scores, according to a study published in Leukemia.1

Researchers evaluated adult patients who were newly diagnosed with Philadelphia positive, BCR-ABL1+ CML across 20 predefined countries in Europe; median observation time was 29 months.

In accordance with European LeukemiaNet recommendations, 80% of patients were treated first-line with imatinib, while 17% were treated with a second generation tyrosine kinase inhibitor (TKI). CCyR was achieved in 57% of treated patients; MMR was achieved in 41% of patients after 12 months.

RELATED: ABCB1 Expression Associated With Response to Imatinib in Chronic Myeloid Leukemia

The probability of overall survival for all observed patients was 97% at 12 months, 94% at 24 months, and 92% at 30 months. The probability of progression-free survival was 95% at 12 months, 92% at 24 months, and 90% at 30 months.

The EUTOS long-term survival (ELTS) score was validated in the present study, with the overall survival of patients differing significantly among the 3 risk groups.

Reference

  1. Hoffman VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2 904 CML patients from the EUTOS population based registry. Leukemia. In press.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters